The market expansion is primarily fueled by the increasing incidence of venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), and other blood-clotting disorders worldwide.
Does an elevated ultrasensitive D-dimer level in a patient whose pre-test probability puts him at low risk for pulmonary embolus (PE) indicate an increased risk for PE or deep venous thrombosis (DVT)?